The $2.2 trillion economic stimulus package, aimed at bolstering the economy against the effects of the SARS-CoV-2 pandemic, has been signed into law by President Trump.
The ID Now COVID-19 test is the second assay from the company to receive EUA from the FDA, following the same designation issued to the Abbott RealTime SARS CoV-2.
The BGI Real-Time Fluorescent RT-PCR Kit for detecting SARS-2019-nCoV runs in approximately three hours and can be manufactured in large volumes, the firm has said.
Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.
Using data for more than half a million individuals, researchers identified 449 refractive area-related loci, including 336 sites not linked to the eye condition in the past.
A new study showed that relying on minimal phenotyping could impede researchers' ability to identify genetic pathways specific to major depressive disorder.
Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.
A new study showed that relying on minimal phenotyping could impede researchers' ability to identify genetic pathways specific to major depressive disorder.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.
Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers.
Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.
